Renal Insufficiency, Chronic
Conditions
Keywords
adapted APD, dwell time, fill volume
Brief summary
The aim of this study is to assess the impact of adapted Automated Peritoneal Dialysis(APD) sequentially prescribed shorter and longer dwell exchanges with smaller and larger fill volumes in comparison with conventional APD prescribed a standard continuous cycling peritoneal dialysis on the efficacy of dialysis.
Detailed description
It is well known that the efficiency of peritoneal dialysis (PD) varies with the duration of the dwell and the prescribed fill volume. Short dwell ensures adequate UF because the osmotic gradient is maintained while prolonged dwell allows for more solute clearance because the dialysate-to-plasma ratio (D/P) for uremic toxins such as creatinine and phosphate enhances. In terms of intraperitoneal fill volume, large fill volume improves the removal of uremic toxins for two reasons: a larger volume can be drained and therefore the clearance achieved is greater, and the peritoneal surface area available for the exchange is increased. Conversely, small fill volume promotes the process of UF because of the potentially low intraperitoneal pressure (IPP). Overall, choosing the optimal dwell time and exchange volume should promote UF and increase the removal of uremic toxins-urea in particular-to the dialysate. Thus, this study proposes a new way of giving PD, using a modified version of conventional prescription which firstly uses 2 cycles of short dwell time with a small fill volume to promote UF and subsequently uses 2 cycles of longer dwell time and a larger fill volume to promote removal of uremic toxins from the blood. Although it was already evaluated the efficiency of this modified prescription by Fischbach et al, the prescription currently prescribed in most Korean hospitals shows some differences in dwell time, fill volume and exchange cycling. The aim of this study is to assess the clinical effect of Korean Adapted APD (KAPD-A) compared to Korean Conventional APD (KAPD-C). This is a multicenter, randomized, open-label, parallel controlled study. Patients who meet inclusion criteria will be randomized into each group at the ratio of 1:1. For incident patients, after being stable on APD and peritonitis-free at least 4 weeks, which is called as run-in period, group 1 will start with 8 weeks of KAPD-C treatment and then cross over to 8 weeks of treatment with KAPD-A while group 2 will be performed on the contrary from KAPD-A to KAPD-C treatment. Each patient will receive the same total amount of dialysate (8000 mL), given over the same 8-hour duration. First at the inclusion visit called as baseline, and then visits will take place every 4 weeks for a total of 16 weeks.
Interventions
PROCEDUREKAPD-C
KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
PROCEDUREKAPD-A
KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
Sponsors
Fresenius Medical Care Korea
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* End stage of Renal Disease(ESRD) patients with indication for renal replacement therapy * D/P Creatinine above 0.5 as evaluated by a 4-hour peritoneal equilibration test(PET) at screening * Stable on APD and peritonitis-free for at least 4 weeks(run-in phase) in case of incident patients who chose APD * Peritonitis-free within 4 weeks in case of maintaining patients who treated with APD in current * Written informed consent to study participation and data submission
Exclusion criteria
* Planned to kidney transplantation within 5 months * Patients with ascites because of the progressed cirrhosis of the liver * Suspected or confirmed pregnancy * Prior enrolment in another clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in overnight peritoneal ultrafiltration (UF) between KAPD-C and KAPD-A | at 4,8,12,16 weeks from baseline |
| Difference in weekly peritoneal Kt/V urea between KAPD-C and KAPD-A | at 4,8,12,16 weeks from baseline |
| Difference in weekly peritoneal creatinine clearance between KAPD-C and KAPD-A | at 4,8,12,16 weeks from baseline |
Secondary
| Measure | Time frame |
|---|---|
| Difference in phosphate dialytic removal between KAPD-C and KAPD-A | at 4,8,12,16 weeks from baseline |
| Difference in corrected for glucose absorption between KAPD-C and KAPD-A | at 4,8,12,16 weeks from baseline |
Countries
South Korea
Outcome results
None listed